Eyelid capillary hemangioma

Summary

Eyelid capillary hemangioma (MONDO:0021627) is a disease. A subtype of capillary hemangioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	eyelid capillary hemangioma
Mondo ID	MONDO:0021627
NCIT	C4357
SNOMED CT	231828003
UMLS	C0339110
MedGen	87379
Anatomy (UBERON)	UBERON:0001711
Is cancer (heuristic)	no

Also known as: capillary angioma of eyelid · capillary angioma of lid · capillary angioma of the eyelid · capillary angioma of the lid · capillary hemangioma of eyelid · capillary hemangioma of lid · capillary hemangioma of the eyelid · capillary hemangioma of the lid · eyelid capillary angioma · eyelid capillary hemangioma

Disease family

This is a subtype of capillary hemangioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › cardiovascular organ benign neoplasm › benign blood vessel neoplasm › hemangioma › capillary hemangioma › eyelid capillary hemangioma

Related subtypes (5): cherry hemangioma, breast capillary hemangioma, capillary infantile hemangioma, hemangioblastoma, pyogenic granuloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.